Skip to main content

Table 1 Patient characteristics and comorbidities; comparison of patients with and without QTc prolongation on EKG

From: Coronavirus disease 2019 (COVID-19) and QTc prolongation

Baseline characteristics All patients (N = 279) QTc prolongation (N = 69) No QTc prolongation (N = 210) P value
Baseline QTc (ms) 430 ± 18 431 ± 20 430 ± 19 0.72
Age 62 ± 17 67 ± 17 60 ± 17 0.003
Sex     
Male, n (%) 145 (52) 39 (57) 106 (51) 0.383
Female, n (%) 134 (48) 30 (44) 104 (50)  
Race     
Caucasian, n (%) 181 (65) 40 (58) 141 (68) 0.097
African-American, n (%) 82 (30) 27 (39) 55 (26)  
Latino, n (%) 13 (5) 1 (1) 12 (6)  
Other, n (%) 2 (1) 1 (1) 1 (1)  
Hypertension, n (%) 197 (70) 53 (77) 144 (67) 0.192
Diabetes mellitus, n (%) 101 (36) 31 (45) 70 (33) 0.082
Cardiovascular disease, n (%) 87 (31) 33 (48) 54 (26) 0.001
Ischemic heart disease, n (%) 55 (20) 20 (29) 35 (17) 0.026
CHFrEF, n (%) 13 (5) 5 (7) 8 (4) 0.240
CHFpEF, n (%) 27 (10) 11 (16) 16 (8) 0.042
Atrial fibrillation, n (%) 28 (10) 11 (16) 17 (8) 0.060
Active cancer, n (%) 12 (4) 3 (4) 9 (4) 0.982
Stroke, n (%) 33 (12) 8 (12) 25 (12) 0.945
Chronic kidney disease, n (%) 37 (13) 16 (23) 21 (10) 0.005
ESRD on HD, n (%) 11 (4) 8 (12) 3 (1) < 0.001
Chronic liver disease, n (%) 13 (5) 6 (9) 7 (3) 0.062
Immunosuppressive state, n (%) 19 (7) 7 (10) 12 (6) 0.193
Home med: ACEi, n (%) 62 (22) 8 (11) 54 (26) 0.014
Home med: ARBs/ARNI, n (%) 32 (12) 8 (12) 24 (11) 0.970
  1. CHFpEF = congestive heart failure with preserved ejection fraction, CHFrEF = congestive heart failure with reduced ejection fraction, ESRD on HD = End stage renal disease on hemodialysis, Immunosuppressive state = anyone on chronic immunomodulatory drugs or with immunodeficiencies such as HIV, ARNI = Angiotensin Receptor-Neprilysin Inhibitor, EKG = Electrocardiogram